Results 121 to 130 of about 3,079 (276)

A Novel Diagnostic Approach for Hepatocellular Carcinoma Using Glycosylated Ferritin

open access: yesHepatology Research, EarlyView.
The percentage of glycosylated ferritin relative to total ferritin (%GF) is a novel biomarker for hepatocellular carcinoma (HCC), showing diagnostic performance comparable to that of AFP and DCP. We developed the GFAD index by integrating age, sex, %GF, AFP, and DCP, achieving improved diagnostic accuracy with high sensitivity and specificity. ABSTRACT
Akiyo Ishiguro   +11 more
wiley   +1 more source

Iron Overload: Pathophysiology, Diagnosis and Monitoring

open access: yesInternational Journal of Laboratory Hematology, EarlyView.
ABSTRACT Iron overload is associated with significant health risks, underscoring the importance of understanding its pathophysiology as well as establishing accurate diagnostic and monitoring methods. Chronic iron overload is associated with either genetic disorders characterized by excessive iron accumulation (hereditary hemochromatosis), or is ...
Elena Chatzikalil   +3 more
wiley   +1 more source

Intrahepatic Cholangiocarcinoma: Epidemiological Trends, Risk Factors, Diagnostic Challenges, and Advances in Personalized Therapy—A Comprehensive Review

open access: yesJournal of Gastroenterology and Hepatology, EarlyView.
ABSTRACT Intrahepatic cholangiocarcinoma (iCCA) ranks as the second most common primary liver cancer, compared to about 20% of cases. Its global incidence has climbed over the past four decades, yet early detection remains indefinable due to its asymptomatic nature. Five‐year survival rate of approximately is under 10%.
Yaqoob Muhammad   +10 more
wiley   +1 more source

Gemcitabine, Docetaxel, Melphalan, Carboplatin as Part of Sequential Cycles of High‐Dose Chemotherapy With Autologous Hematopoietic Stem‐Cell Rescue for Multiply Relapsed/Refractory Pediatric Germ Cell Tumors

open access: yesPediatric Blood &Cancer, Volume 73, Issue 6, June 2026.
ABSTRACT Although most malignant germ cell tumors (GCTs) are highly curable with cisplatin‐based therapy, options for patients with multiply relapsed/refractory disease remain limited. For this population, we report the first pediatric use of gemcitabine, docetaxel, melphalan, and carboplatin (GemDMC) as part of sequential cycles of high‐dose ...
Maria Frost   +10 more
wiley   +1 more source

Clinical Insights From a Case of Sifrim‐Hitz‐Weiss Syndrome With a CHD4 Variant: Expanding the Phenotypic Spectrum and Its Response to Growth Hormone Therapy

open access: yesAmerican Journal of Medical Genetics Part A, Volume 200, Issue 6, Page 1403-1410, June 2026.
ABSTRACT To enhance clinicians' understanding of Sifrim‐Hitz‐Weiss syndrome (SIHIWES), this study investigated the clinical phenotypes, genetic characteristics, and response to growth hormone therapy in a patient. A case of a patient with global developmental delay and distinctive facial features is presented.
Jianmei Zhang   +6 more
wiley   +1 more source

Embryonal Paratesticular Rhabdomyosarcoma Masquerading as an Inguinal Hernia: A Case Report

open access: yesClinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT Embryonal paratesticular rhabdomyosarcoma can mimic benign inguinoscrotal conditions such as inguinal hernia. In children with persistent, painless scrotal masses, early cross‐sectional imaging and prompt radical inguinal orchiectomy with histopathological confirmation are essential.
Somaya Al Kiswani   +7 more
wiley   +1 more source

Impact of Frequent Immune‐Mediated Adverse Events on Treatment Continuity and Outcomes During Durvalumab Plus Tremelimumab Therapy for Unresectable Hepatocellular Carcinoma

open access: yesLiver International Communications, Volume 7, Issue 2, June 2026.
ABSTRACT Durvalumab plus tremelimumab (Dur/Tre) is the first‐line treatment for unresectable hepatocellular carcinoma (uHCC). Immune‐mediated adverse events (imAEs) are common; however, the impact of specific imAE types on treatment persistence and outcomes remains unclear.
Tomomitsu Matono   +53 more
wiley   +1 more source

Home - About - Disclaimer - Privacy